Abbott Laboratories has withdrawn its centralized marketing authorization application with Europe’s EMA for Ozespa, briakinumab, 100 mg solution for injection, for the treatment of moderate to severe chronic plaque psoriasis in adults who failed to respond to, or who are intolerant to other systemic therapies. At the time of the withdrawal it was under review by the agency’s Committee for Medicinal Products for Human Use (CHMP). According to a company statement, the decision was based o...